[{"id":"1356603e-b2dd-488c-b74a-f432af18b9a1","acronym":"DDRiver Solid Tumours 301","url":"https://clinicaltrials.gov/study/NCT04170153","created_at":"2021-06-11T21:52:37.231Z","updated_at":"2025-02-25T12:27:22.944Z","phase":"Phase 1","brief_title":"Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)","source_id_and_acronym":"NCT04170153 - DDRiver Solid Tumours 301","lead_sponsor":"EMD Serono Research \u0026 Development Institute, Inc.","biomarkers":" ARID1A • ATRX","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ARID1A • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • tuvusertib (M1774)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 161","initiation":"Initiation: 12/20/2019","start_date":" 12/20/2019","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-24"},{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"907c18db-1f38-4071-a1e3-b3af86377f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05941520","created_at":"2023-07-12T16:10:13.477Z","updated_at":"2025-02-25T13:49:53.635Z","phase":"Phase 2","brief_title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","source_id_and_acronym":"NCT05941520","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • acolbifene"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/23/2024","start_date":" 08/23/2024","primary_txt":" Primary completion: 08/23/2027","primary_completion_date":" 08/23/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-02-21"},{"id":"a3ff3bf1-6fbc-4e00-b8e0-454d7fb78cce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687136","created_at":"2023-01-18T15:59:53.342Z","updated_at":"2025-02-25T13:41:23.007Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors","source_id_and_acronym":"NCT05687136","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18","pipe":" | ","alterations":" ATM mutation • ARID1A mutation","tags":["ATM • ARID1A • CCNE1 • PBRM1 • FBXW7 • ATRX • ARID1B • ARID2 • SMARCA2 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e peposertib (M3814) • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/07/2024","start_date":" 06/07/2024","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"d4a8f858-34d0-4450-b14d-4588fe783648","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687110","created_at":"2023-01-18T15:59:52.715Z","updated_at":"2025-02-25T16:54:40.188Z","phase":"Phase 1","brief_title":"Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes","source_id_and_acronym":"NCT05687110","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • CDK12 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-04"},{"id":"73183b76-400c-42da-8908-2c1fc21637ec","acronym":"OPTIMUM","url":"https://clinicaltrials.gov/study/NCT05222971","created_at":"2022-02-05T18:29:24.003Z","updated_at":"2025-02-25T17:37:35.916Z","phase":"Phase 2","brief_title":"Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","source_id_and_acronym":"NCT05222971 - OPTIMUM","lead_sponsor":"Asan Medical Center","biomarkers":" BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1","pipe":" | ","alterations":" ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation","tags":["BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 04/01/2022","start_date":" 04/01/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"9b1c2dc1-3b24-43f9-b184-70bf85aad83b","acronym":"NCI-2018-01648","url":"https://clinicaltrials.gov/study/NCT03682289","created_at":"2021-01-18T18:03:10.694Z","updated_at":"2025-02-25T15:07:56.671Z","phase":"Phase 2","brief_title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03682289 - NCI-2018-01648","lead_sponsor":"Rahul Aggarwal","biomarkers":" MSI • ATM • ARID1A • UGT1A1","pipe":" | ","alterations":" ATM mutation","tags":["MSI • ATM • ARID1A • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 89","initiation":"Initiation: 01/17/2019","start_date":" 01/17/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-01-28"},{"id":"04a57d4f-2959-452c-80a6-f0212d657b50","acronym":"","url":"https://clinicaltrials.gov/study/NCT04992013","created_at":"2021-08-05T13:53:09.751Z","updated_at":"2025-02-25T13:12:43.122Z","phase":"Phase 2","brief_title":"Niraparib in Tumors Metastatic to the CNS","source_id_and_acronym":"NCT04992013","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3","pipe":" | ","alterations":" HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • RAD50 • PARP1 • BARD1 • NBN • RAD54L • XRCC2 • RAD54B • XRCC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ATM mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/05/2022","start_date":" 04/05/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-12-12"},{"id":"36a397ed-0e68-47a2-95c4-59ca2210321e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03601923","created_at":"2021-01-18T17:42:32.758Z","updated_at":"2025-02-25T13:18:35.093Z","phase":"Phase 2","brief_title":"Niraparib in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT03601923","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2 • ATM • CHEK2","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CHEK2 mutation","tags":["BRCA1 • BRCA2 • ATM • CHEK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CHEK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/22/2018","start_date":" 08/22/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2024-10-22"},{"id":"9938550f-8e02-48a0-9be9-a575ea84f10a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02677038","created_at":"2021-01-18T13:03:11.604Z","updated_at":"2025-02-25T14:57:29.913Z","phase":"Phase 2","brief_title":"Olaparib in Treating Patients With Stage IV Pancreatic Cancer","source_id_and_acronym":"NCT02677038","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • ATM • HRD • BRCA • RAD51","pipe":" | ","alterations":" HRD • ATM mutation • BRCA mutation","tags":["BRCA1 • ATM • HRD • BRCA • RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • ATM mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 11/11/2016","start_date":" 11/11/2016","primary_txt":" Primary completion: 07/18/2022","primary_completion_date":" 07/18/2022","study_txt":" Completion: 07/18/2022","study_completion_date":" 07/18/2022","last_update_posted":"2024-10-01"},{"id":"9795b4cb-6f73-4ce5-a9a8-6ba8acc8d386","acronym":"Keynote MK-3475-B66","url":"https://clinicaltrials.gov/study/NCT03611868","created_at":"2021-01-18T17:45:12.835Z","updated_at":"2025-02-25T16:08:10.551Z","phase":"Phase 1/2","brief_title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","source_id_and_acronym":"NCT03611868 - Keynote MK-3475-B66","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" ATM mutation • TP53 wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/29/2018","start_date":" 08/29/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-07-19"},{"id":"75a29f57-27bd-4671-83cb-33821417c3f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03047135","created_at":"2021-01-18T15:00:24.273Z","updated_at":"2025-02-25T14:57:49.956Z","phase":"Phase 2","brief_title":"Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis","source_id_and_acronym":"NCT03047135","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 03/01/2017","start_date":" 03/01/2017","primary_txt":" Primary completion: 05/24/2023","primary_completion_date":" 05/24/2023","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-07-03"},{"id":"81538df4-516d-49a5-ada8-8fcdc290500e","acronym":"NCI 9938","url":"https://clinicaltrials.gov/study/NCT02595931","created_at":"2021-07-05T16:47:22.525Z","updated_at":"2024-07-02T16:34:37.311Z","phase":"Phase 1","brief_title":"M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02595931 - NCI 9938","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • berzosertib (M6620)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 07/22/2016","start_date":" 07/22/2016","primary_txt":" Primary completion: 03/07/2023","primary_completion_date":" 03/07/2023","study_txt":" Completion: 12/05/2024","study_completion_date":" 12/05/2024","last_update_posted":"2024-06-07"},{"id":"1b8ee92c-8a75-45d9-be61-ac62bfa9ce43","acronym":"GENTleMEN","url":"https://clinicaltrials.gov/study/NCT03503097","created_at":"2021-01-18T17:14:47.318Z","updated_at":"2024-07-02T16:35:04.196Z","phase":"","brief_title":"Genetic Testing for Men With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03503097 - GENTleMEN","lead_sponsor":"University of Washington","biomarkers":" BRCA1 • HRD","pipe":" | ","alterations":" BRCA1 mutation • HRD • ATM mutation","tags":["BRCA1 • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • HRD • ATM mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 799","initiation":"Initiation: 08/21/2017","start_date":" 08/21/2017","primary_txt":" Primary completion: 08/21/2024","primary_completion_date":" 08/21/2024","study_txt":" Completion: 08/21/2024","study_completion_date":" 08/21/2024","last_update_posted":"2024-05-13"},{"id":"64f232bf-1136-4191-96e8-05f7092ed952","acronym":"COMPRENDO","url":"https://clinicaltrials.gov/study/NCT05033756","created_at":"2021-09-05T16:55:47.679Z","updated_at":"2025-02-25T16:16:39.031Z","phase":"Phase 2","brief_title":"Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO","source_id_and_acronym":"NCT05033756 - COMPRENDO","lead_sponsor":"Institut fuer Frauengesundheit","biomarkers":" HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["HER-2 • PGR • BRCA1 • BRCA2 • ATM • HRD • CHEK2 • RAD51C • RAD51D • BARD1 • XRCC2 • FANCC • SLX4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • PGR positive • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/30/2022","start_date":" 07/30/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-05-07"},{"id":"3fa56835-b064-485b-a887-6a32c8d18aac","acronym":"KNIGHTS","url":"https://clinicaltrials.gov/study/NCT06212583","created_at":"2024-01-19T15:18:40.511Z","updated_at":"2025-02-25T16:27:47.221Z","phase":"Phase 2","brief_title":"High-Risk Metachronous Oligometastatic Prostate Cancer Trial","source_id_and_acronym":"NCT06212583 - KNIGHTS","lead_sponsor":"University of Maryland, Baltimore","biomarkers":" TP53 • BRCA1 • CHEK2 • RAD51B • RAD54L","pipe":" | ","alterations":" ATM mutation • PALB2 mutation","tags":["TP53 • BRCA1 • CHEK2 • RAD51B • RAD54L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 04/17/2024","start_date":" 04/17/2024","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-04-23"},{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"04495210-d346-4ec0-a195-5cf3933896b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05038839","created_at":"2021-09-09T13:53:06.097Z","updated_at":"2024-07-02T16:35:09.419Z","phase":"Phase 1","brief_title":"Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors","source_id_and_acronym":"NCT05038839","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression","tags":["BRCA1 • BRCA2 • PTEN • ARID1A • CHEK2 • RAD50 • PARP1 • CHEK1 • EMSY"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CHEK2 mutation • RAD50 mutation • CHEK1 mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Partruvix (pamiparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/09/2022","start_date":" 02/09/2022","primary_txt":" Primary completion: 06/03/2024","primary_completion_date":" 06/03/2024","study_txt":" Completion: 06/03/2024","study_completion_date":" 06/03/2024","last_update_posted":"2024-04-16"},{"id":"94e4c4f4-2bce-41ab-89c2-a3acf0b6d2b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03250078","created_at":"2021-01-18T16:03:25.897Z","updated_at":"2024-07-02T16:35:12.111Z","phase":"","brief_title":"A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals","source_id_and_acronym":"NCT03250078","lead_sponsor":"Nuvance Health","biomarkers":" BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-04-01"},{"id":"ae2fbbdf-1d9d-47eb-9888-dad360517475","acronym":"MATRIX","url":"https://clinicaltrials.gov/study/NCT05986071","created_at":"2023-08-14T15:09:50.416Z","updated_at":"2025-02-25T16:19:00.084Z","phase":"Phase 1/2","brief_title":"I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers","source_id_and_acronym":"NCT05986071 - MATRIX","lead_sponsor":"Institut Paoli-Calmettes","biomarkers":" HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1","pipe":" | ","alterations":" HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation","tags":["HER-2 • ER • BRCA1 • BRCA2 • ATM • RB1 • ARID1A • CDK12 • ATRX • BRCA • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • RAD54L • FANCL • PPP2R2A • ERCC4 • FANCD2 • XRCC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ATM mutation • ARID1A mutation • PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • tuvusertib (M1774)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 10/15/2027","study_completion_date":" 10/15/2027","last_update_posted":"2024-03-29"},{"id":"2f22aa18-755d-413d-9da7-9cb6d892af4b","acronym":"TRITON3","url":"https://clinicaltrials.gov/study/NCT02975934","created_at":"2021-01-18T14:37:50.152Z","updated_at":"2024-07-02T16:35:13.638Z","phase":"Phase 3","brief_title":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","source_id_and_acronym":"NCT02975934 - TRITON3","lead_sponsor":"pharmaand GmbH","biomarkers":" BRCA1 • BRCA2 • ATM • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • BRCA1 mutation + ATM mutation","tags":["BRCA1 • BRCA2 • ATM • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • BRCA1 mutation + ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide) • Rubraca (rucaparib) • abiraterone acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 405","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 08/25/2022","primary_completion_date":" 08/25/2022","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-20"},{"id":"671d1c67-0f50-43c6-8185-9271e66bda87","acronym":"","url":"https://clinicaltrials.gov/study/NCT05566574","created_at":"2022-10-04T13:56:50.895Z","updated_at":"2024-07-02T16:35:14.602Z","phase":"Phase 1/2","brief_title":"A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05566574","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ATM","pipe":" | ","alterations":" ATM mutation • ATM deletion","tags":["ATM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • ATM deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e camonsertib (RP-3500)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 09/30/2022","start_date":" 09/30/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-15"},{"id":"1bada8c3-f2f1-4030-ad23-c27e1828e629","acronym":"","url":"https://clinicaltrials.gov/study/NCT04550494","created_at":"2021-01-18T21:45:36.970Z","updated_at":"2024-07-02T16:35:16.133Z","phase":"Phase 2","brief_title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","source_id_and_acronym":"NCT04550494","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation","tags":["BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • BAP1 • CDK12 • CHEK2 • RAD51 • FANCA • RAD51B • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • RAD54L • FANCF • FANCL • FANCI • FANCM • BACH1 • FANCD2 • FANCE • FANCG • FANCB • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/26/2021","start_date":" 04/26/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"ac71a659-88ba-460b-8829-91700d494013","acronym":"ORCHID","url":"https://clinicaltrials.gov/study/NCT03786796","created_at":"2021-01-18T18:43:55.909Z","updated_at":"2025-02-25T15:08:13.487Z","phase":"Phase 2","brief_title":"Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations","source_id_and_acronym":"NCT03786796 - ORCHID","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • BAP1 • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/03/2019","start_date":" 06/03/2019","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-05"}]